Roquefort Investments PLC (ROQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Roquefort Investments PLC (ROQ) has a cash flow conversion efficiency ratio of -0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-329.55K ≈ $-40.10 USD) by net assets (GBX4.75 Million ≈ $578.29 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Roquefort Investments PLC - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Roquefort Investments PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Roquefort Investments PLC balance sheet liabilities for a breakdown of total debt and financial obligations.
Roquefort Investments PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roquefort Investments PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lipella Pharmaceuticals Inc. Common Stock
NASDAQ:LIPO
|
-1.585x |
|
CleanTech Lithium plc
LSE:CTL
|
-0.037x |
|
Northern Bear Plc
LSE:NTBR
|
0.121x |
|
Fang Holdings Ltd
NYSE:SFUNY
|
-0.048x |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
0.024x |
|
Trustco Group Holdings
JSE:TTO
|
-0.004x |
|
Sable Exploration and Mining Ltd
JSE:SXM
|
N/A |
|
Greenroc Mining PLC
LSE:GROC
|
-0.055x |
Annual Cash Flow Conversion Efficiency for Roquefort Investments PLC (2021–2024)
The table below shows the annual cash flow conversion efficiency of Roquefort Investments PLC from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see ROQ market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX4.89 Million ≈ $594.85 |
GBX-783.73K ≈ $-95.36 |
-0.160x | +49.14% |
| 2023-12-31 | GBX5.50 Million ≈ $669.14 |
GBX-1.73 Million ≈ $-210.92 |
-0.315x | -44.00% |
| 2022-12-31 | GBX7.21 Million ≈ $876.84 |
GBX-1.58 Million ≈ $-191.93 |
-0.219x | +65.93% |
| 2021-12-31 | GBX4.08 Million ≈ $496.74 |
GBX-2.62 Million ≈ $-319.15 |
-0.642x | -- |
About Roquefort Investments PLC
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more